IFRX · InflaRx N.V.

InflaRx N.V. announced a strategic pivot to focus its lead candidate izicopan, an oral C5a receptor inhibitor, on ANCA-associated vasculitis (AAV) and select renal diseases. The company intends to initiate Phase 2 planning for AAV, leveraging izicopan's potential best-in-class properties including faster onset, higher target coverage, cleaner safety profile, and more convenient dosing compared to the marketed comparator avacopan. Additionally, InflaRx aims to establish rapid proof of concept in other complement-mediated life-threatening kidney diseases such as atypical hemolytic uremic syndrome (aHUS), IgA nephropathy (IgAN), and C3 glomerulopathy (C3G) through open-label studies expected to generate data next year. The company estimates it has sufficient funds to execute these development programs through meaningful milestones, including proof-of-concept data readouts and Phase 2 data in AAV, as well as ongoing operations, through 2029. A Capital Markets Day is planned for summer 2026 to further detail izicopan's potential. InflaRx will also continue to engage in dialog with potential collaborators for global development. The company's pipeline also includes vilobelimab for critical COVID-19 and other indications. This strategic update represents a significant shift in focus and provides a clear development pathway for izicopan, addressing high unmet medical needs in renal diseases.